T. Haahtela et al., EFFECTS OF REDUCING OR DISCONTINUING INHALED BUDESONIDE IN PATIENTS WITH MILD ASTHMA, The New England journal of medicine, 331(11), 1994, pp. 700-705
Background. In a previous study, we found that two years of treatment
with an inhaled corticosteroid, budesonide, was more effective than tr
eatment with an inhaled beta(2)-agonist, terbutaline, in patients with
newly diagnosed, generally mild asthma. We continued this study for a
third year to investigate whether the steroid dose could be reduced o
r discontinued and what effect crossover of patients from beta(2)-agon
ist therapy to corticosteroid therapy would have. Methods. A total of
37 patients treated for two years with inhaled budesonide at a dose of
1200 mu g per day were randomly assigned to treatment with 400 mu g o
f budesonide per day (19 patients) or placebo (18 patients) in a doubl
e-blind manner. Another 37 patients, who had received terbutaline duri
ng the first two years, were crossed over in an open-label manner to t
reatment with 1200 mu g of budesonide per day during the third year. R
esults. Treatment with the reduced dose of budesonide was sufficiently
effective in 74 percent of the patients to maintain bronchial respons
iveness at a level similar to that achieved with the higher dose. In c
ontrast, improvement was maintained in only 33 percent of the patients
receiving placebo, and the differences in pulmonary function between
the steroid and placebo groups were significant (for forced expiratory
volume in one second, P = 0.007; for bronchial responsiveness to hist
amine, P = 0.025; and for peak expiratory flow in the morning, P = 0.0
40). The condition of patients who were crossed over from terbutaline
therapy to treatment with 1200 mu g of budesonide per day improved. Ho
wever, the degree of improvement in these patients appeared to be less
than in those who were treated with budesonide at the beginning of th
e three-year study. Conclusions. Early treatment with inhaled budesoni
de results in long-lasting control of mild asthma. Maintenance therapy
can usually be given at a reduced dose, but discontinuation of treatm
ent is often accompanied by exacerbation of the disease.